EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes



Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes



Leukemia 7(9): 1324-1327



The effect of human recombinant erythropoietin (rhEPO) was investigated in 29 anemic patients with myelodysplastic syndromes (MDS). A rhEPO dosage of 150 U/kg was administered subcutaneously three times weekly for a minimum of 6 weeks. Seven out of 27 evaluable patients (26%) had an effective clinical response to therapy by increasing hemoglobin concentrations by more than 15 g/l (reaching at least 105 g/l) or by eliminating transfusion requirements. Six out of the seven patients responded within four weeks. Three of the responders successfully continued rhEPO treatment 15 months or more. To determine whether it may be possible to predict response to rhEPO, various clinical parameters were examined. Responders were found to be significantly different from non-responders in five aspects: They had less elevated baseline serum EPO levels (92 +/- 33 versus 515 +/- 108 U/l, mean +/- SEM; p = 0.023) and were more often transfusion-independent (71% versus 20% of non-responders; p = 0.022). Furthermore, responders were more often females (71% versus 40% in the non-responding group; p = 0.025), of subtype RA rather than RAEB (four patients and one patient, respectively, compared to seven and nine patients in the non-responding group; p = 0.025), and they predominantly displayed normal karyotypes or a 5q- aberration (86% versus 47%; p = 0.005). We conclude, that rhEPO treatment can reduce anemia in MDS and that certain pre-treatment clinical parameters may be used to predict response.

(PDF emailed within 1 workday: $29.90)

Accession: 009228333

Download citation: RISBibTeXText

PMID: 8371582



Related references

Response to recombinant human erythropoietin treatment in myelodysplastic syndromes (MDS). Journal of Internal Medicine 229(4): 381-382, 1991

Recombinant human erythropoietin in the treatment of myelodysplastic syndromes--response patterns. Leukemia & Lymphoma 15(1-2): 149-152, 1994

Sustained resolution of anemia without any treatment after excessive therapeutic response to human recombinant erythropoietin in three patients with myelodysplastic syndromes. Supportive Care in Cancer 21(7): 1803-1805, 2014

Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic syndromes. Haematologica 78(2): 118-122, 1993

Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment. Haematologica 95(2): 339-340, 2010

Treatment of myelodysplastic syndromes with recombinant human erythropoietin. European Journal of Haematology 47(5): 355-360, 1991

Recombinant human erythropoietin for treatment of myelodysplastic syndromes. Leukemia 6(4): 323-327, 1992

Treatment of myelodysplastic syndromes with recombinant human erythropoietin. Experimental Hematology (Charlottesville) 20(6): 773, 1992

Clinical Use of Recombinant Human Erythropoietin in the Treatment of Myelodysplastic Syndromes. Leukemia and Lymphoma 7(Sup2): 99-99, 1992

Recombinant human erythropoietin rh epo a possible treatment for the anemia of myelodysplastic syndromes mds. Leukemia Research 15(SUPPL): 32, 1991

Recombinant human erythropoietin for the treatment of anaemia in the myelodysplastic syndromes. Leukemia Research 15(SUPPL): 22, 1991

Treatment of anemia in myelodysplastic syndromes with recombinant human erythropoietin. Sangre 38(4): 340-341, 1993

The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. British Journal of Haematology 77(3): 419-423, 1991

Is recombinant human erythropoietin treatment in myelodysplastic syndromes worthwhile?. Leukemia & Lymphoma 9(1-2): 79-83, 1993

Treatment of myelodysplastic syndromes with a combination of recombinant human interleukin-3 and erythropoietin. British Journal of Haematology 87(SUPPL 1): 157, 1994